Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252146 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
A Phase 1 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02252146 is a Phase 1 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT02252146, a Phase 1 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of the Toll Like Receptors (TLRs), including the endosomal TLRs 7, 8, and 9, for which the ligands are nucleic acids. IMO-8400 is an oligonucleotide specifically designed to inhibit ligand activation of TLRs 7,8, and 9. Recent studies indicate that in the presence of L265P mutation ligand activation of those TLRs results in markedly increased signaling with subsequent increased cell activation, cell survival, and cell proliferation. The scientific rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P mutation is based on laboratory observations that IMO-8400 inhibits ligand-based activation of cells with the mutation and decreases the survival and proliferation of the cell populations responsible for the propagation of the disease.
Interventions
- DRUG IMO-8400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02252146
The ClinicalTrials.gov registry entry for NCT02252146 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMO-8400 is the first listed.
NCT02252146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02252146 about?
NCT02252146 is a clinical study titled "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation". Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of the Toll Like Receptors (TLR...
What is the current status of trial NCT02252146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02252146?
The interventions under investigation include: IMO-8400 (DRUG).
Who is sponsoring clinical trial NCT02252146?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.